专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR20180042272A 항-PSMA 항체, PSMA 및 CD3에 결합하는 이특이적 항원-결합 분자, 및 이들의 용도 审中-公开
公开(公告)号：KR20180042272A
公开(公告)日：2018-04-25
申请号：KR20187005964
申请日：2016-07-29
申请人： REGENERON PHARMA
发明人： KIRSHNER JESSICA R , CRAWFORD ALISON , THURSTON GAVIN , SMITH ERIC , HABER LAURIC , DUDGEON DREW , RAFIQUE ASHIQUE
IPC分类号： C07K16/28 , A61K39/00 , A61P35/00 , C07K16/30
CPC分类号： C07K16/3069 , A61K2039/505 , C07K16/2809 , C07K2317/31 , C07K2317/33 , C07K2317/73 , C07K2317/92
摘要： 본발명은전립선-특이적막 항원(PSMA)에결합하는항체, PSMA 및 CD3에결합하는이중특이성항체, 및이들의사용방법을제공한다. 특정실시형태에따르면, 본발명의항체는고친화도로인간 PSMA에결합하고, 인간 T 세포증식을유도하기위해 CD3에결합한다. 본개시내용은 PSMA 및 CD3에결합하고, PSMA-발현종양세포의 T 세포-매개사멸을유도하는항체를포함한다. 특정실시형태에따르면, 본발명은인간 CD3에특이적으로결합하는제1 항원-결합도메인, 및인간 PSMA에특이적으로결합하는제2 항원-결합분자를포함하는이중특이성항원-결합분자를제공한다. 특정실시형태에서, 본개시내용의이중특이성항원-결합분자는 PSMA를발현시키는전립선종양의성장을저해할수 있다. 본개시내용의항체및 이중특이성항원-결합분자는상향조절또는유도된표적화된면역반응이요망되고/되거나치료적으로유리한질환및 장애의치료에유용하다. 예를들어, 본발명의항체는다양한암의치료에유용하다.

2. 发明专利

RS63660B1 ANTI-MUC16 (MUCIN 16) ANTITELA 未知
公开(公告)号：RS63660B1
公开(公告)日：2022-11-30
申请号：RSP20220906
申请日：2017-09-22
申请人： REGENERON PHARMA
发明人： HABER LAURIC , SMITH ERIC , KELLY MARCUS , KIRSHNER JESSICA R , COETZEE SANDRA , CRAWFORD ALISON , NITTOLI THOMAS , LIU YASHU
IPC分类号： C07K16/30 , A61K39/395 , C07K16/28 , C07K16/44 , C07K16/46

3. 发明专利

ES2925563T3 Anticuerpos anti-MUC16 (Mucina 16) 未知
公开(公告)号：ES2925563T3
公开(公告)日：2022-10-18
申请号：ES17787989
申请日：2017-09-22
申请人： REGENERON PHARMA
发明人： HABER LAURIC , SMITH ERIC , KELLY MARCUS , KIRSHNER JESSICA R , COETZEE SANDRA , CRAWFORD ALISON , NITTOLI THOMAS , LIU YASHU
IPC分类号： C07K16/30 , A61K39/395 , C07K16/28 , C07K16/44 , C07K16/46
摘要： La mucina 16 (MUC16) se expresa en gran medida en el cáncer de ovario y se ha demostrado que la expresión en las células cancerosas protege a las células tumorales del sistema inmunitario. La presente invención proporciona nuevos anticuerpos IgG humanos de longitud completa que se unen a humanos y MUC16 (anticuerpos monoespecíficos). La presente invención también proporciona nuevos anticuerpos biespecíficos (bsAbs) que se unen tanto a MUC16 como a CD3 y activan las células T a través del complejo CD3 en presencia de tumores que expresan MUC16. De acuerdo con ciertas realizaciones, la presente invención proporciona moléculas de unión a antígeno biespecíficas que comprenden un primer dominio de unión a antígeno que se une específicamente a CD3 humana y de mono, y una segunda molécula de unión a antígeno que se une específicamente a MUC16 humana y de mono. En ciertas realizaciones, las moléculas de unión a antígeno biespecíficas de la presente invención son capaces de inhibir el crecimiento de tumores que expresan MUC16. Las moléculas de unión a antígeno biespecíficas de la invención son útiles para el tratamiento de enfermedades y trastornos en los que se desea y/o es terapéuticamente beneficiosa una respuesta inmunitaria dirigida a MUC16 regulada al alza o inducida. Por ejemplo, los anticuerpos biespecíficos de la invención son útiles para el tratamiento de diversos tipos de cáncer, incluido el cáncer de ovario. La presente invención también incluye conjugados de fármaco de anticuerpo anti-MUC16 que inhiben el crecimiento tumoral in vivo. En algunas realizaciones, los anticuerpos anti-MUC16 son útiles en métodos de diagnóstico para identificar la presencia de MUC16 en muestras de tejido y/o plasma. (Traducción automática con Google Translate, sin valor legal)

4. 发明专利

MA56537A UTILISATION DE MOLÉCULES DE LIAISON À L'ANTIGÈNE BISPÉCIFIQUES QUI SE LIENT À MUC16 ET CD3 EN COMBINAISON AVEC UNE CO-STIMULATION DE 4-1BB 未知
公开(公告)号：MA56537A
公开(公告)日：2022-04-27
申请号：MA56537
申请日：2020-06-19
申请人： REGENERON PHARMA
发明人： CHIU DANICA , CRAWFORD ALISON , KIRSHNER JESSICA R
IPC分类号： A61K39/00 , C07K16/28 , C07K16/30 , C07K16/46

5. 发明专利

AU2020294790A1 Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation 未知
公开(公告)号：AU2020294790A1
公开(公告)日：2021-12-16
申请号：AU2020294790
申请日：2020-06-19
申请人： REGENERON PHARMA
发明人： KIRSHNER JESSICA R , CRAWFORD ALISON , CHIU DANICA
IPC分类号： C07K16/28 , A61K39/00 , C07K16/30 , C07K16/46
摘要： Provided herein are method of treating cancer using bispecific antigen-binding molecules that bind to Mucin 16 (MUC16) and CD3. According to certain embodiments, the antibodies useful herein bind human MUC16 with high affinity and bind CD3 to induce human T cell proliferation. According to certain embodiments, bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human MUC16 are particularly useful herein. In certain embodiments, the bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are capable of inhibiting the growth of tumors expressing MUC16, for example, ovarian tumors. The bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial, for example, in the treatment of various cancers.

6. 发明专利

ZA201703290B METHODS FOR TUMOR TREATMENT USING CD3XCD20 BISPECIFIC ANTIBODY 未知
公开(公告)号：ZA201703290B
公开(公告)日：2021-06-30
申请号：ZA201703290
申请日：2017-05-12
申请人： REGENERON PHARMA
发明人： SMITH ERIC , DAVIS SAMUEL , VARGHESE BINDU , KIRSHNER JESSICA R , THURSTON GAVIN , LOWY ISRAEL , BROWNSTEIN CARRIE
摘要： The present invention relates to a method (dosage regimen) for administering a CD3 x CD20 bispecific antibody to a human patient, comprising (a) administering a first dose of said antibody in a specific dosage; and consecutively (b) administering a second dose of said antibody after a period of time, wherein said second dose exceeds said first dose. The methods of the invention (and likewise the dosage regimen of the invention) are also suitable for treating B cell (CD20-positive) cancer in a human patient, or for ameliorating and/or preventing a medical condition medicated by the periodic or continued administration of a CD3 x CD20 bispecific antibody to a human patient. The present invention also relates to the use of a CD3 x CD20 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method or treatment regime as defined in any one of the preceding claims. A pharmaceutical package or kit comprising the first dose, the second dose, and any subsequent doses are also part of the present invention.

7. 发明专利

DK3594238T3 Antistofsammensætninger til tumorbehandling 未知
公开(公告)号：DK3594238T3
公开(公告)日：2021-04-19
申请号：DK19188693
申请日：2015-03-18
申请人： REGENERON PHARMA
发明人： DAVIS SAMUEL , SMITH ERIC , VARGHESE BINDU , KIRSHNER JESSICA R , THURSTON GAVIN
IPC分类号： C07K16/28 , A61K39/395

8. 发明专利

CA3139827A1 USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3 IN COMBINATION WITH 4-1BB CO-STIMULATION 未知
公开(公告)号：CA3139827A1
公开(公告)日：2020-12-24
申请号：CA3139827
申请日：2020-06-19
申请人： REGENERON PHARMA
发明人： KIRSHNER JESSICA R , CRAWFORD ALISON , CHIU DANICA
IPC分类号： C07K16/46 , A61K39/00 , C07K16/28 , C07K16/30 , C07K16/40
摘要： Provided herein are methods of treating cancer using bispecific antigen-binding molecules that bind to prostate-specific membrane antigen (PSMA) and CD3. According to certain embodiments, the antibodies useful herein bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. According to certain embodiments, bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA are particularly useful herein. In certain embodiments, the bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are capable of inhibiting the growth of prostate tumors expressing PSMA. The bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial, for example, in the treatment of various cancers.

9. 发明专利

CL2019003802A1 Proteínas de unión al antígeno anti-virus de papiloma humano (hpv) y sus métodos de uso. 未知
公开(公告)号：CL2019003802A1
公开(公告)日：2020-06-12
申请号：CL2019003802
申请日：2019-12-20
申请人： REGENERON PHARMA
发明人： BRAY KEVIN A , DELFINO FRANK , FRANKLIN MATTHEW C , GARNOVA ELENA S , KIRSHNER JESSICA R , MACDONALD DOUGLAS , OLSON WILLIAM , THURSTON GAVIN
IPC分类号： A61P31/20 , C07K16/08 , C07K16/28
摘要： PROTEÍNAS DE UNIÓN AL ANTÍGENO QUE SE UNEN ESPECÍFICAMENTE A UN PÉPTIDO DEL VIRUS DE PAPILOMA HUMANO (HPV) EXPRESADO SOBRE HLA, Y CON MÉTODOS TERAPÉUTICOS Y DE DIAGNÓSTICO PARA USAR DICHAS PROTEÍNAS DE UNIÓN.

10. 发明专利

HUE046505T2 Antitestkészítmények daganatkezelésre 未知
公开(公告)号：HUE046505T2
公开(公告)日：2020-03-30
申请号：HUE15714116
申请日：2015-03-18
申请人： REGENERON PHARMA
发明人： DAVIS SAMUEL , SMITH ERIC , VARGHESE BINDU , KIRSHNER JESSICA R , THURSTON GAVIN
IPC分类号： C07K16/28 , A61P35/02

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式